Importance of myeloid derived suppressor cells in cancer from a biomarker perspective
Suresh Gopi Kalathil, Yasmin Thanavala, Suresh Gopi Kalathil, Yasmin Thanavala
Abstract
Myeloid derived suppressor cells (MDSC) are a heterogenous population of immature myeloid cells that accumulate in tumor bearing host and migrate to lymphoid organs and tumor tissues. This process is controlled by a set of defined pro-inflammatory cytokines and chemokines, which are upregulated in malignancies. MDSC have strong immunosuppressive potential and constitute a major component of the tumor microenvironment (TME). Tumor cells take advantage of the suppressive mechanisms of MDSC to establish an immunosuppressive TME which inhibits antitumor immune responses thereby promoting cancer progression. An immunosuppressive TME acts as a significant barrier to immunotherapeutic interventions. Pre-clinical and clinical studies have demonstrated that enrichment and activation of MDSC is correlated with tumor progression, recurrence and metastasis. In this review we discuss the potential impact of MDSC on tumor progression and its role as a biomarker of prognostic significance in cancer with a special focus on hepatocellular cancer (HCC).
Trial registration: ClinicalTrials.gov NCT01835223.
Keywords: Biomarker; HCC; Immunotherapy; MDSC; Tumor microenvironment.
Copyright © 2020 Elsevier Inc. All rights reserved.
Source: PubMed